Low-cost Bioproduction PlantForm’s vivoXPRESS plant-based manufacturing platform claims significantly reduced costs for producing biologic drugs and vaccines, presenting a compelling value proposition for pharmaceutical partners seeking cost efficiencies in biosimilars and emerging therapies.

Rapid Deployment The platform can enable drug production in as little as six weeks, offering speed-to-market advantages for new biosimilars, vaccines, or outbreak-response programs that require accelerated timelines.

Biosimilar Focus Pipeline interests include biosimilars of high-profile drugs like Lucentis and Keytruda, signaling a clear opportunity to engage in co-development, manufacturing partnerships, and regional launches, particularly in markets with demand for lower-cost alternatives.

Strategic Partnerships Recent collaborations with Bio-Manguinhos/Fiocruz, UBC, and other research institutions indicate openness to joint development, licensing, and contract manufacturing arrangements that could be extended to global partners seeking plant-based capabilities.

Growing Market Readiness Active engagements in Brazil, Canada, and academic partnerships, plus experience in producing diagnostics and edible antibodies, suggest opportunities across biotech, veterinary, and human health sectors where rapid, scalable manufacturing is valued.